Tumor microenvironment contributes to Epstein-Barr virus anti-nuclear antigen-1 antibody production in nasopharyngeal carcinoma

Ai,Ping; Li,Zhiping; Jiang,Yong; Song,Changping; Zhang,Lin; Hu,Huaizhong; Wang,Tao

doi:10.3892/ol.2017.6461

Tumor microenvironment contributes to Epstein-Barr virus anti-nuclear antigen-1 antibody production in nasopharyngeal carcinoma

Authors:
- Ping Ai
- Zhiping Li
- Yong Jiang
- Changping Song
- Lin Zhang
- Huaizhong Hu
- Tao Wang
View Affiliations

Affiliations: Department of Head and Neck Oncology, Cancer Center, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Abdominal Oncology, Cancer Center, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Laboratory of Molecular and Translational Medicine, Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 22, 2017 https://doi.org/10.3892/ol.2017.6461
Pages: 2458-2462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear antigen-1 (NA1) protein of Epstein‑Barr virus (EBV) is expressed in EBV‑infected cells in the microenvironment of cancer. Since immune cells infiltrate abundantly in nasopharyngeal carcinoma (NPC) tumor tissues, we hypothesized that the local tumor microenvironment may perform an important role in the production of antibodies directed at NA1. Furthermore, we hypothesized that anti‑NA1 antibody originating in the local microenvironment could be secreted into the saliva of patients with NPC. In the present study, 20 healthy controls and 39 patients with NPC treated with intensity‑modulated radiation therapy were recruited for the study. Saliva and serum samples were collected from the NPC patients, and nasopharyngeal tissue samples from the patients with NPC. The titers of anti‑NA1 antibody [immunoglobulin A (IgA)] were determined by ELISA. Expression of NA1, human leukocyte antigen‑antigen D related (HLA‑DR), cluster of differentiation (CD)80, CD86, CD3, CD4, CD19 and IgA was detected by immunohistochemical staining on paraffin‑embedded nasopharyngeal tissue sections. Anti‑NA1 antibodies were detected in the serum and saliva samples of the patients with NPC. In infiltrating cells, expression of HLA‑DR, CD80, CD86, CD3, CD4, CD19 and IgA was detected, indicating that dendritic cells, T lymphocytes and B lymphocytes were all present in the local tumor tissues. Furthermore, expression of EBNA1 protein was detected on the membrane of the NPC tumor cells. Therefore, the NPC tumor microenvironment has the potential to initiate a humoral response to EBNA1 by producing IgA antibodies.

View Figures

View References

1	Chen JN, Ding YG, Feng ZY, Li HG, He D, Du H, Wu B and Shao CK: Association of distinctive Epstein-Barr virus variants with gastric carcinoma in Guangzhou, southern China. J Med Virol. 82:658–667. 2010. View Article : Google Scholar : PubMed/NCBI
2	Deng Z, Hasegawa M, Matayoshi S, Kiyuna A, Yamashita Y, Maeda H and Suzuki M: Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol. 268:1625–1631. 2011. View Article : Google Scholar : PubMed/NCBI
3	Garandawa HI, Ahmad BM and Nggada HA: Nasopharyngeal cancer in North-Eastern Nigeria: Clinical trends. Niger J Clin Pract. 12:379–382. 2009.PubMed/NCBI
4	Popat SR, Liavaag PG, Morton R, McIvor N, Irish JC and Freeman JL: Epstein Barr virus genome in nasopharyngeal carcinomas from New Zealand. Head Neck. 22:505–508. 2000. View Article : Google Scholar : PubMed/NCBI
5	Rathaur RG, Chitale AR and Banerjee K: Epstein-Barr virus in nasopharyngeal carcinoma in Indian patients. Indian J Cancer. 36:80–90. 1999.PubMed/NCBI
6	Valencia SM and Hutt-Fletcher LM: Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells. J Virol. 86:2–10. 2012. View Article : Google Scholar : PubMed/NCBI
7	Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB and Rowe M: Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: Viral genome expression, genome maintenance and genome amplification. J Virol. 83:7749–7760. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gaur N, Gandhi J, Robertson ES, Verma SC and Kaul R: Epstein-Barr virus latent antigens EBNA3C and EBNA1 modulate epithelial to mesenchymal transition of cancer cells associated with tumor metastasis. Tumour Biol. 36:3051–3060. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kang MS and Kieff E: Epstein-Barr virus latent genes. Exp Mol Med. 47:e1312015. View Article : Google Scholar : PubMed/NCBI
10	Palser AL, Grayson NE, White RE, Corton C, Correia S, Ba Abdullah MM, Watson SJ, Cotten M, Arrand JR, Murray PG, et al: Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. J Virol. 89:5222–5237. 2015. View Article : Google Scholar : PubMed/NCBI
11	Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI and Rowe M: Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology. 474:117–130. 2015. View Article : Google Scholar : PubMed/NCBI
12	Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W and Prasad U: Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer. 45:1061–1064. 1990. View Article : Google Scholar : PubMed/NCBI
13	Finger PT: 7th Edition, AJCC-UICC Ophthalmic Oncology Task Force: The 7th edition AJCC staging system for eye cancer: An international language for ophthalmic oncology. Arch Pathol Lab Med. 133:1197–1198. 2009.PubMed/NCBI
14	Cheng HM, Foong YT, Sam CK, Prasad U and Dillner J: Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol. 29:2180–2186. 1991.PubMed/NCBI
15	Tedeschi R, Pin E, Martorelli D, Bidoli E, Marus A, Pratesi C, Bortolin MT, Zanussi S, Vaccher E, Dolcetti R and De Paoli P: Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity. Clin Vaccine Immunol. 14:435–441. 2007. View Article : Google Scholar : PubMed/NCBI
16	Tang JW, Rohwäder E, Chu IM, Tsang RK, Steinhagen K, Yeung AC, To KF and Chan PK: Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J Clin Virol. 40:284–288. 2007. View Article : Google Scholar : PubMed/NCBI
17	Paramita DK, Fachiroh J, Haryana SM and Middeldorp JM: Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. J Clin Virol. 42:343–352. 2008. View Article : Google Scholar : PubMed/NCBI
18	Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R and Middeldorp JM: Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol. 75:593–602. 2005. View Article : Google Scholar : PubMed/NCBI
19	Cho WC: Nasopharyngeal carcinoma: Molecular biomarker discovery and progress. Mol Cancer. 6:12007. View Article : Google Scholar : PubMed/NCBI
20	Ai P, Wang T, Zhang H, Wang Y, Song C, Zhang L, Li Z and Hu H: Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma. Oral Oncol. 49:326–331. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yao QY, Rowe M, Morgan AJ, Sam CK, Prasad U, Dang H, Zeng Y and Rickinson AB: Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer. 48:45–50. 1991. View Article : Google Scholar : PubMed/NCBI
22	Nadala EC, Tan TM, Wong HM and Ting RC: ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus. J Med Virol. 50:93–96. 1996. View Article : Google Scholar : PubMed/NCBI